Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Teva
Chinese Patent Office
Baxter
Farmers Insurance
Colorcon

Generated: March 24, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RIVASTIGMINE

« Back to Dashboard

Clinical Trials for Rivastigmine

Trial ID Title Status Sponsor Phase Summary
NCT00099216 Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed Novartis Pharmaceuticals Phase 3 The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.
NCT00099242 Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease Completed Novartis Phase 3 The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
NCT00102284 Neuromodulation and Language Acquisition (Project Stage Ia) Terminated University Hospital Muenster Phase 4 The purpose of this study is to determine whether levodopa, pergolid, rivastigmine, or modafinil are effective in boosting semantic language acquisition in healthy subjects.
NCT00102856 Neuromodulation and Language Acquisition (Stage Ib) Suspended University Hospital Muenster Phase 4 The purpose of this study is to determine whether rivastigmine or pramipexol are effective in boosting semantic language acquisition in healthy subjects.
NCT00130338 Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed Novartis Phase 3 The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.
NCT00134953 Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment Terminated Novartis Phase 3 This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with mild cognitive impairment (MCI).
NCT00154635 Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease Unknown status Development Center for Biotechnology, Taiwan Phase 2 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer’s Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Rivastigmine

Condition Name

Condition Name for Rivastigmine
Intervention Trials
Alzheimer's Disease 28
Alzheimer Disease 10
Delirium 6
Parkinson's Disease 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Rivastigmine
Intervention Trials
Alzheimer Disease 45
Dementia 18
Cognition Disorders 10
Parkinson Disease 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Rivastigmine

Trials by Country

Trials by Country for Rivastigmine
Location Trials
United States 146
Japan 44
Netherlands 17
Canada 17
Italy 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Rivastigmine
Location Trials
Texas 11
California 10
New York 9
Florida 9
Pennsylvania 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Rivastigmine

Clinical Trial Phase

Clinical Trial Phase for Rivastigmine
Clinical Trial Phase Trials
Phase 4 32
Phase 3 25
Phase 2/Phase 3 1
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Rivastigmine
Clinical Trial Phase Trials
Completed 57
Terminated 7
Unknown status 6
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Rivastigmine

Sponsor Name

Sponsor Name for Rivastigmine
Sponsor Trials
Novartis 19
Novartis Pharmaceuticals 14
National Institute on Drug Abuse (NIDA) 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Rivastigmine
Sponsor Trials
Other 85
Industry 52
NIH 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
UBS
AstraZeneca
Johnson and Johnson
Argus Health
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.